Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42345 (
mTOR
)
26,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Protein translation initiation is a tightly controlled process responding to nutrient availability and mitogen stimulation. Serving as one of the most important negative regulators of protein translation, 4E binding protein 1 (4E-BP1) binds to translation initiation factor 4E and inhibits cap-dependent translation in a phosphorylation-dependent manner. Although it has been demonstrated previously that the phosphorylation of 4E-BP1 is controlled by
mammalian target of rapamycin
in the
mammalian target of rapamycin
complex 1, the mechanism underlying the dephosphorylation of 4E-BP1 remains elusive. Here, we report the identification of
PPM1G
as the phosphatase of 4E-BP1. A coimmunoprecipitation experiment reveals that
PPM1G
binds to 4E-BP1 in cells and that purified
PPM1G
dephosphorylates 4E-BP1 in vitro. Knockdown of
PPM1G
in 293E and colon cancer HCT116 cells results in an increase in the phosphorylation of 4E-BP1 at both the Thr-37/46 and Ser-65 sites. Furthermore, the time course of 4E-BP1 dephosphorylation induced by amino acid starvation or
mammalian target of rapamycin
inhibition is slowed down significantly in
PPM1G
knockdown cells. Functionally, the amount of 4E-BP1 bound to the cap-dependent translation initiation complex is decreased when the expression of
PPM1G
is depleted. As a result, the rate of cap-dependent translation, cell size, and protein content are increased in
PPM1G
knockdown cells. Taken together, our study has identified protein phosphatase
PPM1G
as a novel regulator of cap-dependent protein translation by negatively controlling the phosphorylation of 4E-BP1.
...
PMID:Protein phosphatase PPM1G regulates protein translation and cell growth by dephosphorylating 4E binding protein 1 (4E-BP1). 2381 53